NUC 3373

Drug Profile

NUC 3373

Alternative Names: 5-Fluorouracil ProTide - NuCana; NUC-3373

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiff University
  • Developer NuCana
  • Class Antineoplastics; Pyrimidine nucleotides
  • Mechanism of Action DNA methylation inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Colorectal cancer; Solid tumours

Most Recent Events

  • 08 Sep 2017 Interim pharmacokinetics data from a phase I trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017) (ADNM)
  • 15 Dec 2016 Biomarkers information updated
  • 22 Jul 2016 Phase-I clinical trials in Breast cancer and Colorectal cancer (unspecified route) (NuCana pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top